122 related articles for article (PubMed ID: 4644648)
1. Canadian experience.
Cook D
Pharmacology; 1972; 8(1):190-8. PubMed ID: 4644648
[No Abstract] [Full Text] [Related]
2. Proceedings: The comparison of the bioavailabilities of commercial nitrofurantoin tablets.
McGilveray IJ; Mattok GL; Hossie RD
Rev Can Biol; 1973; 32():Suppl:99-106. PubMed ID: 4777608
[No Abstract] [Full Text] [Related]
3. Comparative bioavailabilities from truncated blood level curves.
Lovering EG; McGilveray IJ; McMillan I; Tostowaryk W
J Pharm Sci; 1975 Sep; 64(9):1521-4. PubMed ID: 1185570
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
[No Abstract] [Full Text] [Related]
5. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
Schnieders B
Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
[TBL] [Abstract][Full Text] [Related]
6. The importance of biopharmaceutics in pharmaceutical education.
Mezei M
Pharmazie; 1971 Nov; 26(11):656-8. PubMed ID: 5154315
[No Abstract] [Full Text] [Related]
7. QUAD routes out inferior drugs.
Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804
[No Abstract] [Full Text] [Related]
8. Non-equivalent preparations of the same drug.
Drug Ther Bull; 1971 Aug; 9(17):65-8. PubMed ID: 5123964
[No Abstract] [Full Text] [Related]
9. Assuring total drug quality.
Simmons HE
J Am Pharm Assoc; 1973 Feb; 13(2):96-8. PubMed ID: 4686621
[No Abstract] [Full Text] [Related]
10. A study of bioavailabilities and dissolution rates of commercial tablets of nitrofurantoin.
McGilveray IJ; Mattok GL; Hossie RD
J Pharm Pharmacol; 1971 Dec; 23():246S. PubMed ID: 4401504
[No Abstract] [Full Text] [Related]
11. In vitro drug release rate as a standard requirement.
Láng B
Pharmazie; 1971 Nov; 26(11):661-4. PubMed ID: 5154319
[No Abstract] [Full Text] [Related]
12. Determination of physiologic availability of commercial phenylbutazone preparations.
Chiou WL
J Clin Pharmacol New Drugs; 1972 Jul; 12(7):296-300. PubMed ID: 4483535
[No Abstract] [Full Text] [Related]
13. Proceedings: The effect of food intake and sleep on the absorption of acetaminophen.
Mattok GL; McGilveray IJ
Rev Can Biol; 1973; 32():Suppl:77-84. PubMed ID: 4777605
[No Abstract] [Full Text] [Related]
14. Biopharmaceutics of nitrofurantoin.
Conklin JD
Pharmacology; 1972; 8(1):178-81. PubMed ID: 4644646
[No Abstract] [Full Text] [Related]
15. The general problem of drug bioavailability and its assessment in man.
Smith RN
Postgrad Med J; 1974 Nov; 50 Suppl 6():7-14. PubMed ID: 4459894
[No Abstract] [Full Text] [Related]
16. Canadian health ministry is given new powers to tighten drug safety.
Dyer O
BMJ; 2014 Jun; 348():g4231. PubMed ID: 24962373
[No Abstract] [Full Text] [Related]
17. [Influence of dosage form on drug effect].
Zathurecký L
Pharmazie; 1972 Nov; 27(11):686-93. PubMed ID: 4650983
[No Abstract] [Full Text] [Related]
18. [Tolerance ansd effectiveness of a new nitrofurantoin dosage form in healthy subjects and patients with renal insufficiency].
Lais J
Wien Med Wochenschr; 1971 Jul; 121(27):553-9. PubMed ID: 5002695
[No Abstract] [Full Text] [Related]
19. The physiologic availability of solid dosage forms of phenylbutazone. I. In vivo physiologic availability and pharmacologic considerations.
Van Petten GR; Feng H; Withey RJ; Lettau HF
J Clin Pharmacol New Drugs; 1971; 11(3):177-86. PubMed ID: 5211351
[No Abstract] [Full Text] [Related]
20. Keeping bioavailability in perspective.
Schumacher GE
Am J Hosp Pharm; 1973 Feb; 30(2):150-4. PubMed ID: 4690469
[No Abstract] [Full Text] [Related]
[Next] [New Search]
